• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常和恶性乳腺组织中的X因子激活促凝血剂

Factor X-activating procoagulant in normal and malignant breast tissue.

作者信息

el-Baruni K, Taylor I, Roath S, Francis J L

机构信息

University Department of Haematology, Southampton General Hospital, U.K.

出版信息

Hematol Oncol. 1990 Nov-Dec;8(6):323-32. doi: 10.1002/hon.2900080604.

DOI:10.1002/hon.2900080604
PMID:2286355
Abstract

Factor X-activating activity (FXAA) was determined by a chromogenic assay in normal and malignant breast tissue. FXAA was found in all tissue (n = 38) irrespective of pathology, and the activity of normal tissue was similar to that of tumours. FXAA correlated with tissue hemoglobin in normal breast (p less than 0.02) but not in tumours. FXAA was markedly reduced by aluminium hydroxide, barium citrate, anti-human factor VII, DFP, PMSF and phospholipase C, but was unaffected by iodoacetamide and mercuric chloride. It is concluded that FXAA is a serine protease with the properties of a tissue factor-factor VII complex. FXAA occurs in normal and malignant breast tissue, although the 'normal' activity may be an artefact of the homogenization process.

摘要

采用显色法在正常和恶性乳腺组织中测定X因子激活活性(FXAA)。在所有组织(n = 38)中均检测到FXAA,无论其病理状态如何,且正常组织的活性与肿瘤组织相似。在正常乳腺组织中,FXAA与组织血红蛋白相关(p < 0.02),但在肿瘤组织中无此相关性。FXAA可被氢氧化铝、柠檬酸钡、抗人因子VII、二异丙基氟磷酸(DFP)、苯甲基磺酰氟(PMSF)和磷脂酶C显著降低,但不受碘乙酰胺和氯化汞的影响。得出的结论是,FXAA是一种具有组织因子-因子VII复合物特性的丝氨酸蛋白酶。FXAA存在于正常和恶性乳腺组织中,尽管“正常”活性可能是匀浆过程中的人为产物。

相似文献

1
Factor X-activating procoagulant in normal and malignant breast tissue.正常和恶性乳腺组织中的X因子激活促凝血剂
Hematol Oncol. 1990 Nov-Dec;8(6):323-32. doi: 10.1002/hon.2900080604.
2
Factor X-activating activity in normal and malignant colorectal tissue.正常和恶性结直肠组织中的X因子激活活性。
Thromb Res. 1988 Nov 1;52(3):207-17. doi: 10.1016/0049-3848(88)90080-1.
3
A factor X-activating cysteine protease from malignant tissue.一种来自恶性组织的X因子激活半胱氨酸蛋白酶。
J Clin Invest. 1981 Jun;67(6):1665-71. doi: 10.1172/jci110203.
4
Factor X-activating activity in patients with colorectal carcinoma.结直肠癌患者中因子X激活活性
Br J Surg. 1987 Dec;74(12):1122-4. doi: 10.1002/bjs.1800741216.
5
Procoagulant properties of benign and malignant prostatic tissue.良性和恶性前列腺组织的促凝血特性。
Br J Urol. 1994 Aug;74(2):204-9. doi: 10.1111/j.1464-410x.1994.tb16587.x.
6
Procoagulant activity of gastric, colorectal, and renal cancer is factor VII-dependent.胃癌、结直肠癌和肾癌的促凝血活性依赖于凝血因子VII。
J Cancer Res Clin Oncol. 1988;114(5):519-22. doi: 10.1007/BF00391504.
7
Factor X-activating activity from Guerin epithelioma.来自格林上皮瘤的X因子激活活性。
Neoplasma. 1988;35(3):279-84.
8
Comparison of procoagulant activities in extracts of normal and malignant human tissue.正常和恶性人体组织提取物中促凝血活性的比较。
J Natl Cancer Inst. 1979 Apr;62(4):773-6.
9
Phenylmethylsulfonyl fluoride alters sensitivity to organophosphorus-induced delayed neurotoxicity in developing animals.苯甲基磺酰氟会改变发育中动物对有机磷诱导的迟发性神经毒性的敏感性。
Neurotoxicology. 1992 Summer;13(2):355-64.
10
Different expression of procoagulant activity in human cancer cells cultured "in vitro" or in cells isolated from human tumor tissues.人癌细胞在“体外”培养或从人肿瘤组织分离的细胞中促凝血活性的不同表达。
Thromb Haemost. 1993 Apr 1;69(4):335-8.

引用本文的文献

1
Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.促凝血活性可能是实验性前列腺癌恶性表型的一个标志物。
Br J Cancer. 1994 Feb;69(2):286-90. doi: 10.1038/bjc.1994.53.
2
Tissue procoagulant activity may be important in sustaining metastatic tumour growth.组织促凝活性在维持转移性肿瘤生长中可能很重要。
Clin Exp Metastasis. 1992 May;10(3):175-81. doi: 10.1007/BF00132749.
3
Non-tissue factor procoagulants in cancer cells.癌细胞中的非组织因子促凝剂。
Cancer Metastasis Rev. 1992 Nov;11(3-4):267-82. doi: 10.1007/BF01307182.
4
Tissue factor as a tumor procoagulant.组织因子作为一种肿瘤促凝剂。
Cancer Metastasis Rev. 1992 Nov;11(3-4):249-66. doi: 10.1007/BF01307181.